IL6 and tuberculosis: Treatment with SB20358 or PD98059 further decreased the release of TNF-α (by 83.0% or 74.0%, respectively) or IL-6 (by 69.5% or 66.7%, respectively) from AM of TB patients (Fig. 5A,B).